Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study (UNIFAI)

April 18, 2024 updated by: Friedreich's Ataxia Research Alliance
This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The UNIFAI Study: Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study is a global research study designed to provide a deep and evolving understanding of the natural history of this rare and debilitating genetic disorder as well as inform clinical trial design and implementation.

Friedreich's Ataxia is a rare, inherited, multi-system condition characterized by progressive neurological and cardiac symptoms. It is caused by mutations in the FXN (frataxin) gene.

The UNIFAI study is a multicenter, prospective, longitudinal, observational study, which means that all data about the natural disease course will be captured at study visits conducted annually according to a single protocol for all sites. This study will recruit participants with FA worldwide, to be assessed annually for up to 25 years. Study participation involves yearly study visits with data collected from medical records and history along with clinical outcome assessments including, neurological exams, timed walking tests, upper limb function measures, and patient-reported quality of life assessments, with the option for sites to collect additional ancillary measures related to speech, vision, fatigue, balance and cognition.

This global study is a harmonization of two well-established, long-standing natural history studies in FA that have provided a framework for further investigation of clinical measures that can quantitatively assess FA: FACOMS (US, Canada, Australia, New Zealand, and India) and EFACTS (European countries). These studies have been conducted in parallel with many similarities in study conduct. Uniting these two existing studies and groups of researchers gives greater power to data previously collected as well as future data. It also continues efforts to expand the network of clinical research centers specializing in FA called the FA-Global Clinical Consortium.

Due to advances in understanding the genetic and cellular dysfunction of FA that lead to symptoms observed in affected individuals, there has been significant growth in the discovery and development of therapeutic approaches, many currently being evaluated in clinical trials and a first approved treatment in the United States in 2023. The UNIFAI study aims to build upon this momentum by focusing on several key objectives.

UNIFAI will assess the natural history of FA by collecting data from diagnosed individuals of all ages and stages of disease progression. The data collected includes demographics, medical history, medications, neurological and functional assessments, cardiac examinations, laboratory studies, and health questionnaires. The study will assess and evaluate clinical outcomes in individuals with FA, such as disease progression, symptom severity, and overall quality of life, by various factors that might influence such outcomes such as genetic mutation, demographics (age, geography), co-existing conditions, medications, or treatments. By tracking outcomes over time, researchers aim to discern patterns, trends, and potential variations in subgroups or in the effectiveness of therapies or interventions across a diverse group of participants.

The UNIFAI study aims to play a pivotal role in identifying clinical milestones and changes in natural history over time as new treatments emerge. The study will monitor how these interventions alter the trajectory of the disease, potentially leading to the identification of crucial tipping points, disease landmarks, or stages where interventions can be most impactful. This study has the potential to significantly improve our understanding of FA and lead to more effective treatments and improved outcomes for those living with FA.

The study aims to inform clinical trial design and the development and validation of novel clinical outcome assessments and biomarkers that can be used in clinical trials. The UNIFAI study aims to capture data from a wide and diverse cohort of individuals with FA so that this dataset can be used to inform the selection of inclusion and exclusion criteria and power calculations for trial designs with specific clinical outcome measures.

Study Type

Observational

Enrollment (Estimated)

3000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Australia
    • Victoria
      • Parkville, Victoria, Australia, 3052
        • Recruiting
        • Murdoch Childrens Research Institute
        • Contact:
        • Principal Investigator:
          • Martin Delatycki, MD
        • Contact:
  • Austria
      • Innsbruck, Austria, 6020
        • Not yet recruiting
        • Medical University Innsbruck, Department of Neurology
        • Principal Investigator:
          • Sylvia Boesch, MD
        • Sub-Investigator:
          • Wolfgang Nachbauer, MD
        • Contact:
  • Belgium
  • Brazil
      • Campinas, Brazil
        • Not yet recruiting
        • University of Campinas
        • Contact:
        • Principal Investigator:
          • Marcondes França, MD, PhD
  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • Not yet recruiting
        • The Hospital for Sick Children
        • Principal Investigator:
          • Grace Yoon, MD
        • Contact:
    • Quebec
      • Montreal, Quebec, Canada, H9R 2Y2
        • Not yet recruiting
        • McGill University Health Centre - Montreal Neurological Institute
        • Principal Investigator:
          • Massimo Pandolfo, MD
        • Principal Investigator:
          • Maryam Oskoui, MD
        • Contact:
      • Montréal, Quebec, Canada, h2x0a9
        • Recruiting
        • CHUM - Hopital Notre-Dame
        • Principal Investigator:
          • Antoine Duquette, MD
        • Contact:
  • Czechia
      • Praha, Czechia, 150 06
        • Not yet recruiting
        • Motol University Hospital, Centre for Hereditary Ataxias
        • Principal Investigator:
          • Martin Vyhnálek, MD
        • Contact:
          • Lucie Šťovíčková
          • Phone Number: +420 22443-3302,-3334 ext (Chi
          • Email: ataxie@fnmotol.cz
        • Contact:
  • France
      • Paris, France, 75013
        • Not yet recruiting
        • Paris Brain Institute
        • Principal Investigator:
          • Alexandra Durr, MD
        • Contact:
      • Strasbourg, France, 67098
        • Not yet recruiting
        • Hôpital de Hautepierre, Service de Neurologie
        • Principal Investigator:
          • Mathieu Anheim, MD
        • Contact:
  • Germany
      • Aachen, Germany, 52074
        • Not yet recruiting
        • University Hospital Aachen, Dept. of Neurology
        • Principal Investigator:
          • Jörg B. Schulz, MD
        • Contact:
        • Principal Investigator:
          • Kathrin Reetz, MD
      • Bonn, Germany, 53105
        • Not yet recruiting
        • Deutsches Zentrum Für Neurodegenerative Erkrankungen
        • Principal Investigator:
          • Thomas Klockgether, MD
      • Munich, Germany, 80336
        • Not yet recruiting
        • University of Munich, Dept. of Neurology, Friedrich-Baur-Institut
        • Principal Investigator:
          • Thomas Klopstock, MD
        • Contact:
        • Principal Investigator:
          • Ivan Karin, MD
      • Tübingen, Germany, 72076
        • Not yet recruiting
        • University of Tübingen, Dept. of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research
        • Contact:
        • Principal Investigator:
          • Ludger Schöls, MD
  • Greece
      • Athens, Greece, 11528
        • Not yet recruiting
        • National and Kapodistrian University of Athens, Neurogenetics Unit
        • Contact:
        • Principal Investigator:
          • Georgios Koutsis
  • India
    • NCT
      • New Delhi, NCT, India, 110020
        • Recruiting
        • All India Institute Of Medical Sciences (AIIMS)
        • Contact:
        • Contact:
        • Principal Investigator:
          • Achal Srivastava, MD
        • Sub-Investigator:
          • Mohammed Faruq, M.B.B.S., PhD
  • Ireland
      • Dublin, Ireland, D24 TP66
        • Not yet recruiting
        • Tallaght University Hospital, Department of Neurology
        • Contact:
        • Principal Investigator:
          • Sinead Murphy, MD
        • Principal Investigator:
          • Richard Walsh, MD
  • Italy
      • Conegliano, Italy, 21015
        • Not yet recruiting
        • Referente Clinico-Scientifico di Polo IRCCS "E. Medea"
        • Principal Investigator:
          • Andrea Martinuzzi, MD
        • Contact:
          • Andrea Martinuzzi
      • Milan, Italy, 20133
        • Not yet recruiting
        • Fondazione IRCCS Istituto Neurologico Carlo Besta
        • Principal Investigator:
          • Caterina Mariotti, MD
        • Sub-Investigator:
          • Lorenzo Nanetti, MD
        • Contact:
      • Roma, Italy, 00146
        • Not yet recruiting
        • Bambino Gesù Children's Hospital, Department of Neurosciences
        • Principal Investigator:
          • Enrico Bertini, MD
        • Contact:
  • Netherlands
      • Nijmegen, Netherlands, 6525
        • Not yet recruiting
        • Stichting Radboud Universitair Medisch Centrum
        • Contact:
        • Principal Investigator:
          • Bart van De Warrenburg, MD
  • New Zealand
      • Auckland, New Zealand, 1023
        • Recruiting
        • Auckland City Hospital
        • Principal Investigator:
          • Richard Roxburgh, BSC MB PhD
        • Contact:
  • Spain
      • Barcelona, Spain, 08950
        • Not yet recruiting
        • Hospital Sant Joan de Déu, Servicio de Neurología
        • Principal Investigator:
          • Francesc Palau Martinez, MD
        • Contact:
      • Madrid, Spain, 28046
        • Not yet recruiting
        • Hospital Universitario La Paz, Servicio de Neurologia
        • Principal Investigator:
          • Francisco J. Rodriguez de Rivera Garrido, MD
        • Contact:
  • United Kingdom
      • London, United Kingdom, WC1N 3 BG
        • Not yet recruiting
        • University College of London, Ataxia Centre, National Hospital for Neurology and Neurosurgery
        • Principal Investigator:
          • Paola Giunti, MD
        • Contact:
  • United States
    • California
      • Los Angeles, California, United States, 90095
        • Recruiting
        • UCLA Ataxia Center
        • Principal Investigator:
          • Susan Perlman, MD
        • Contact:
    • Colorado
      • Denver, Colorado, United States, 80045
        • Recruiting
        • University of Colorado
        • Principal Investigator:
          • Trevor Hawkins, MD
        • Contact:
    • Florida
      • Gainesville, Florida, United States, 32610
        • Recruiting
        • University of Florida - Neurology
        • Contact:
        • Principal Investigator:
          • SH Subramony, MD
      • Tampa, Florida, United States, 33612
        • Recruiting
        • USF Ataxia Research Center
        • Principal Investigator:
          • Theresa Zesiewicz, MD
        • Contact:
          • FA Study
          • Phone Number: 813-947-5633
    • Georgia
      • Atlanta, Georgia, United States, 30329
        • Recruiting
        • Emory University Hospital - Neurology
        • Principal Investigator:
          • George Wilmot, MD
        • Contact:
          • UNIFAI Study
          • Phone Number: 404-727-1509
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • Not yet recruiting
        • University of Iowa, Stead Family Children's Hospital
        • Contact:
        • Principal Investigator:
          • Katherine Mathews, MD
    • Ohio
      • Columbus, Ohio, United States, 43221
        • Not yet recruiting
        • Ohio State University - Neurology
        • Contact:
        • Principal Investigator:
          • Chad Hoyle, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Recruiting
        • Children's Hospital of Philadelphia
        • Contact:
        • Principal Investigator:
          • David Lynch, MD PhD
    • Tennessee
      • Memphis, Tennessee, United States, 38105
        • Not yet recruiting
        • St. Jude Children's Research Hospital
        • Contact:
        • Principal Investigator:
          • Richard Finkel, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study will include current participants from the existing FA-COMS and EFACTS natural history studies as well as enroll new individuals with Friedreich ataxia (FA) and healthy controls.

Description

Inclusion Criteria:

  1. Both males and females of any age
  2. Individuals with Friedreich ataxia (FA): Participants that meet genetically confirmed diagnosis of Friedreich ataxia

  3. Written informed consent provided

    1. Informed consent must be obtained for all participants
    2. For underage participants, they and the parent/ legally authorized representative have to sign the informed consent form, child assent (if applicable)
    3. Persons who are not legally competent require the informed consent of their legally authorized representative

    Exclusion Criteria:

  4. Unable or unwilling to provide informed consent
  5. Acute or ongoing medical or other conditions that would interfere with the conduct and assessments of the study
  6. For any reason in the opinion of the investigator, participant would be unlikely or unable to comply with study protocol requirements.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in modified Friedreich Ataxia Rating Scale (mFARS) Score
Time Frame: Baseline, Year 1-25
The modified Friedreich Ataxia Rating Scale (mFARS) is a disease-specific scale that measures progression of neurological effects of FA. The mFARS is a validated and reliable scale; comprised of the neurologic component of the FARS and evaluates bulbar, upper limb, lower limb, and upright stability/gait function. For each item, responses categorize the corresponding neurological finding, and the findings are assigned a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. The score ranges from 0 to 93. The score will be compared to the previous year annually for up to 25 years.
Baseline, Year 1-25
Change in Scale for the Assessment and Rating of Ataxia (SARA) Score
Time Frame: Baseline, Year 1-25
The Scale for the Assessment and Rating of Ataxia (SARA) is a semi-quantitative assessment of ataxia, measuring ataxia of upper limb, lower limb, gait, balance and speech. It has eight items: gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movement, and heel-shin slide. The total score ranges from 0 (no ataxia) to 40 (severe ataxia). The score will be compared to the previous year annually for up to 25 years.
Baseline, Year 1-25
Change in FA Activities of Daily Living (ADL) Score
Time Frame: Baseline, Year 1-25
The FARS-ADL is a subsection of the FARS questionnaire that assesses activities of daily living, including speech, personal hygiene, feeding, and mobility. Participants rank each category using a scale of 0 (normal) to 4 (severe disability/ inability to carry out activity independently), with lower scores indicative of "normal" function/activity. The score will be compared to the previous year annually for up to 25 years.
Baseline, Year 1-25
Change in Upright Stability (US) Score
Time Frame: Baseline, Year 1-25
The Upright Stability (US) assessment is part of the neurological examination within the Modified Friedreich Ataxia Rating Scale (mFARS). This component comprises nine items: sitting position, stance with feet apart, stance with feet apart and eyes closed, stance with feet together, stance with feet together and eyes closed, tandem stance, stance with dominant foot, tandem walk, and gait. The score ranges from 0 to 9, with a higher score reflecting poorer upright stability (i.e., greater neurological severity). The score will be compared to the previous year annually for up to 25 years.
Baseline, Year 1-25

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in 9-hole peg test mean time (seconds)
Time Frame: Baseline, Year 1-25
The 9 Hole Peg Test (9HPT) examines finger dexterity and involves placing and removing nine pegs in a pegboard in the quickest possible time. Two consecutive trials of the dominant hand, followed immediately by two consecutive trials of the non-dominant hand, are undertaken. The average time in seconds taken to complete the task, for each of the dominant and non-dominant hand, is calculated. The 9HPT has high intra- and inter-rater reliability and is the most commonly used measure of upper limb function in FA. The score will be compared to the previous year annually for up to 25 years.
Baseline, Year 1-25
Change in Timed walk (25-foot or 8-meter) mean time (seconds)
Time Frame: Baseline, Year 1-25
The timed 25-foot/8-meter walk examines upright stability, balance and mobility and involves walking a predetermined distance. Two consecutive trials are undertaken. The average time in seconds taken to complete the task, is calculated. The score will be compared to the previous year annually for up to 25 years.
Baseline, Year 1-25
Change in Speech analysis scores
Time Frame: Baseline, Year 1-25
A battery of speech evaluations will be administered and recorded on a laptop for analysis, using Redenlab software. This will include: reading of a phonetically-balanced passage, sustained vowel sound, listing days of the week, repeating syllables, and a monologue task. This will form a measure of dysarthria. Redenlab is a US-Australian speech-testing company, https://redenlab.com. The score will be compared to the previous year annually for up to 25 years.
Baseline, Year 1-25
Change in Ataxia Instrumented Measures (AIMs)clinical severity score
Time Frame: Baseline, Year 1-25
The Ataxia Instrumented Measures (AIMs) system consists of three components: 1) the data logger which is either a spoon, cup or pendant each containing sensors, Wi-Fi and processor; 2) algorithms that distinguishes between movements made by control and users with ataxia and grades the severity of ataxia when detected; and 3) ataxia scores presented in a manner that has utility for clinicians (the AIM "score"). This score is continuous and features an ataxia severity threshold which has been established through the process of machine learning and is based on the separation between individuals with ataxia and control participants. Any value below the severity threshold of a specific device is expected for controls/very mild ataxia, and any value beyond is expected for individuals with moderate/severe ataxia. The score will be compared to the previous year annually for up to 25 years.
Baseline, Year 1-25
Change in Lower Contrast Letter Acuity test score
Time Frame: Baseline, Year 1-25
Contrast letter acuity for vision will be assessed using back-lit Low-Contrast Sloan Letter Charts (LCSLCs). Participants will sit at an eye distance of 2 metres from the chart. Binocular vision will be assessed using participants' normal corrective lenses where relevant. Participants are required to read each letter on the chart. Three charts will be presented, with three different visual contrast levels: 100% (equivalent to high-contrast visual acuity), 2.5%, and 1.25%. The maximum total score across the three charts (number of letters read correctly) is 240. Scores for each individual chart will also be recorded.
Baseline, Year 1-25

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Friedreich's Ataxia Research Alliance

Investigators

  • Principal Investigator: David Lynch, MD, Children's Hospital of Philadelphia
  • Principal Investigator: Jorg B Schulz, Prof, University Hospital, Aachen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 28, 2023

Primary Completion (Estimated)

January 28, 2048

Study Completion (Estimated)

January 28, 2048

Study Registration Dates

First Submitted

August 18, 2023

First Submitted That Met QC Criteria

August 23, 2023

First Posted (Actual)

August 30, 2023

Study Record Updates

Last Update Posted (Actual)

April 19, 2024

Last Update Submitted That Met QC Criteria

April 18, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1016

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Friedreich Ataxia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe